Company
Australian medical-device company developing targeted radiation treatments
Sydney, NSW
Every investor coverage indicates participated in a round OncoSil Medical raised.
Companies OncoSil Medical acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Nigel Lange | Chief Executive and Managing Director | Biotech Dispatch (9 Sep 2026), Biotech Dispatch (18 Aug 2026), @AuManufacturing (28 May 2025), @AuManufacturing (22 Mar 2024) |
Stories naming OncoSil Medical. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
OncoSil Medical says a Madrid hospital has treated its 100th Spanish pancreatic cancer patient with its brachytherapy device, as the ASX-listed company focuses on deepening use across its 11 treatment sites.
OncoSil Medical has raised $5.6m from three large existing shareholders to fund overseas and domestic launches of its radiation therapy, after winning TGA and FDA clearances for pancreatic and bile duct cancer use.
Australian device maker OncoSil Medical has won US FDA humanitarian exemption approval for its targeted radiation treatment for unresectable distal bile duct cancer, opening a path to American commercialisation in financial year 2027.
Manufacturing roundup: OncoSil Medical locks in commitments for an $8.7 million raise, Soilco completes its purchase of Martins Fertilizers, Avecho collects an R&D rebate, alongside items on apprenticeships, Myriota, Recce and Swinburne research.
Also thecfigroup.com·divestmergeacquire.com·redchip.com.au·wastemanagementreview.com.au
Roundup of Australian manufacturing news: OncoSil, K-TIG and Aurora Labs complete or commit raises, Amplia opens an offer, Siemens agrees to buy Altair, CSIRO unveils a printed-solar facility, and a WA medical alliance grows.
Roundup of Australian manufacturing news: OncoSil Medical's capital raising, an NT grant for a water monitoring project, GoZero's preferred supplier appointment, Micro-X's first Argus order, Aurora Labs' defence work, and Monash waste-recycling research.